Acute promyelocytic leukemia (APL) accounts for 10% to 15% of all cases of acute myeloid leukemia, with some reports registering a higher percentage in pediatric and Latino patient populations. 1,2 APL is genetically characterized by fusion of the promyelocytic leukemia (PML) and retinoic acid receptor α (RARα) genes as a result of t(15;17)(q22;q12), leading to expression of a novel PML-RARα protein. PML-RARα is a unifying signature of APL; however, other features can be variable. [3] [4] [5] In particular, there are 2 morphologic variants of APL, macrogranular (M3) and microgranular (M3v), with some differences in their immunophenotype. 6 Although APL is remarkably responsive to current therapeutic protocols, with a complete response rate of 90%, up to 30% of patients have a relapse. [7] [8] [9] [10] [11] [12] [13] The approach for establishing the diagnosis of relapse in patients with APL relies on the presumption that recurrent disease will be similar to the neoplasm before therapy. However, the characteristics of APL at the time of relapse are not well described in the literature.
Despite the success of the current therapy for patients with acute promyelocytic leukemia (APL), relapse occurs in up to
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In this study, we evaluated the morphologic, immunophenotypic, cytogenetic, and molecular features of APL at the time of relapse and compared the findings with those of the original, pretherapy neoplasm. The results show that although the blast morphologic features are stable, immunophenotypic and cytogenetic changes are common.
Materials and Methods

Cases
This retrospective study spans the interval January 1, 1992, to December 31, 2008, and draws from a pool of 207 patients with APL treated at The University of Texas M.D.
Anderson Cancer Center, Houston. Every case of APL in this study was confirmed by the presence of t(15;17) (q22;q12) or PML-RARα fusion identified by conventional cytogenetic analysis, fluorescence in situ hybridization, and/ or reverse transcription-polymerase chain reaction (RT-PCR). All human subjects were protected in accordance with the Helsinki declaration. All cases were classified using the World Health Organization and French-American-British classification systems. Cases of APL with rare variant translocations, for example t(5;17), were not identified.
The study group included 38 patients with morphologic evidence of relapsed APL. This subset represented 18% of all patients with APL. Cases with only molecular evidence of relapsed APL were not included in the study group.
Flow Cytometric Immunophenotypic Analysis
We performed 3-or 4-color flow cytometry immunophenotypic analysis on peripheral blood and/or bone marrow (BM) aspirate specimens collected in EDTA as previously described. 14 After incubation of cells with a panel of monoclonal antibodies for 10 minutes at 4°C, the RBCs were lysed with NH 4 Cl for 10 minutes, followed by 2 washing steps using phosphate-buffered saline. The cells then were resuspended and fixed with 1% paraformaldehyde. The panel of monoclonal antibodies used was variable over time but included reagents specific for CD2, CD3, CD7, CD9, CD10, CD13, CD19, CD20, CD33, CD34, CD38, CD64, CD117, myeloperoxidase, HLA-DR, and terminal deoxynucleotidyl transferase. All antibodies were purchased from Becton Dickinson Biosciences, San Jose, CA. Analysis was performed using a FACScan or FACSCalibur cytometer (Becton Dickinson Biosciences). For each antibody, negative staining levels were set by comparison with an isotype-matched control.
Conventional Cytogenetic Analysis
Conventional G-band karyotype analysis was performed on BM aspirate specimens at diagnosis and at relapse as described previously. 15 Briefly, cells were placed in 10 mL of Ham F10 medium with 20% fetal serum at a concentration of 2 to 4 × 10 6 /mL nucleated cells. Cultures were incubated at 37°C for approximately 24 hours. Standard harvesting procedures were used. Colcemid (0.1 mL/10mL) was added to the culture for 30 minutes at room temperature. For hypotonic treatment, 0.075 mol/L potassium chloride was used for 30 minutes at room temperature. The karyotype reports were written using the International System for Human Cytogenetic Nomenclature 1995. 16 
Reverse Transcription-PCR
Real-time qualitative RT-PCR was performed to detect PML-RARα transcripts as previously described. 14 Total RNA was extracted from peripheral blood or BM aspirate specimens, and complementary DNA was synthesized using 1 to 2 μg of total RNA, random hexamer primers, and 300 U of Superscript II (Invitrogen, Houston, TX). RT-PCR was performed using the primers P3 (5'-ACCGATGGCTTCGACGAGTTC-3') and R4a (5'-AGCCCTTGCAGCCCTCACAG-3'). The values were normalized to ABL transcript levels and expressed as a ratio of PML-RARα to ABL product. The sensitivity of the test was approximately 1 in 10 6 .
Results
Study Group
There were 26 males and 12 females of ages ranging from 1 to 80 years (mean, 44 years) at initial diagnosis ❚Table 1❚. At initial diagnosis 34 patients had classic macrogranular morphologic features (M3), and 4 patients had the microgranular variant (M3v). In 34 patients, disease was de novo, and 4 had therapy-related APL. Although the slides of all pretherapy specimens were reviewed in our department, some patients were initially diagnosed and received therapy at other institutions before coming to M.D. Anderson Cancer Center.
The treatment regimen used after the initial diagnosis of APL included 23 patients who received all-trans-retinoic acid (ATRA) plus chemotherapy (4 also received arsenic) and 12 patients who received liposomal ATRA. The regimen was unknown in 3 patients.
A subset of patients was tested for the presence of additional genetic aberrations at initial diagnosis, and 8, 5, and 2 patients were negative for RAS, MLL, and KIT mutations, respectively. Of the 6 patients tested for the presence of FLT3 mutations, 4 had negative results. Internal tandem duplication and a D835 mutation were detected in 1 patient each. There were a total of 55 morphologic relapses: 1 relapse in 25 patients, 2 relapses in 9 patients, and 3 relapses in 4 patients. The time to first relapse ranged from 6 to 65 months (mean, 20.2 months), the time from first to second relapse ranged from 7 to 39 months (mean, 15 months), and the time from second to third relapse ranged from 5 to 12 months (mean, 9.5 months). Of these patients, 30 had relapse only in the BM. One patient had 1 extramedullary relapse in the breast and a second relapse in the BM; 1 patient had a skin relapse without BM involvement; 3 patients had central nervous system relapse (2 with and 1 without concurrent BM involvement); 1 patient had a first relapse in the BM and a second relapse in the skin and cerebrospinal fluid without BM involvement; 1 patient had a relapse in soft tissue (an infraspinous mass) without BM involvement and a second relapse in the skin with BM involvement; and 1 patient had a relapse as bilateral external auditory canal lesions (without erosion of underlying bone) with concurrent BM involvement.
Comparison of Conventional Cytogenetic Findings at Initial Diagnosis and Relapse
Complete conventional cytogenetic data were available at initial diagnosis for 20 cases. In 16 cases, the t(15;17) (q22;q11) was present as an isolated abnormality, and all therapy-related APL cases were a part of this category. In 4 cases, the karyotype showed 3 or more abnormalities, including t(15;17) ❚Table 2❚.
Conventional cytogenetic data were available at first relapse in 20 cases, and comparison with the initial pretreatment material was possible in 10. In 6 of them, there was no change, and in 4 cases there were changes, including 1 case with an additional marker chromosome, 1 case with a der(9)t(9;11)(q34;q13), 1 case with multiple additional structural abnormalities, and 1 case with structural changes of chromosome 17.
Among 10 cases at first relapse with an unknown karyotype before therapy, 6 cases had t(15;17) as an isolated abnormality and 4 cases had t(15;17) with additional changes. These additional aberrations included 2 cases with trisomy 8; 1 case with t(3;8)(q26.2;q13), monosomies of X and 8, and trisomies of 10 and 21; and 1 case with monosomies of 1, 7, and 14 with marker chromosomes.
At the second relapse, conventional cytogenetic data were available in 5 cases, and comparison with the karyotype at first relapse was possible in 3. In 1 case, there was no change, and in 2 cases, additional cytogenetic abnormalities were shown. In 1 case, a complex karyotype including t(3;5) (q29;q21) developed, and in 1 case, a complex karyotype developed including inversions of chromosomes 1, 7, and 14 and partial deletion of chromosome 6p.
At third relapse, conventional cytogenetic data were available in 4 cases, and comparison with a previous karyotype 
Comparison of RT-PCR Amplicons at Initial Diagnosis and Relapse
The length of the PML-RARα fusion transcript was determined at initial diagnosis in 18 cases (11 long and 7 short transcripts), at first relapse in 30 cases, at second relapse in 8 cases, and at third relapse in 3 cases. Comparison of transcript size at initial diagnosis and at various relapses showed no changes.
Comparison of Flow Cytometric Immunophenotypic Results at Initial Diagnosis and Relapse
Comparison of the flow cytometric immunophenotypic data at initial diagnosis and at the first relapse was possible in 9 cases. In 8 cases (89%), loss, gain, or changes in intensity of antigen expression involving one or more markers were detected. Three cases had changes in 1 marker, 4 cases had changes in 2 markers, and 1 case had changes in 3 markers.
The most frequent changes at relapse were detected in CD13 expression, with loss in 2 cases and substantially decreased intensity in 3 cases. One case, initially CD117-, developed CD117+ promyelocytes at relapse, and CD117 expression was increased in 3 additional cases. Two cases with initially CD33-APL had CD33+ results at relapse, and 1 case with HLA-DR-APL at initial diagnosis gained HLA-DR expression at relapse. Two cases, in which the promyelocytes were CD34-at initial diagnosis became positive at relapse, and the intensity of CD34 expression further increased at time of the second relapse in 1 case.
In 23 cases, flow cytometric immunophenotypic analysis was performed on an initial (12 cases) or relapsed APL (11 cases) specimen, but without another specimen for comparison. All cases were HLA-DR-. CD34 was positive in 4 relapsed cases of APL, whereas only 2 APL cases at initial diagnosis were CD34+ (1 of which had microgranular morphologic features).
Comparison of Morphologic Features at Initial Diagnosis and Relapse
In 37 cases, the morphologic features were stable ❚Image 1A❚ and ❚Image 1B❚. The stable group included all 4 patients with M3v morphologic features. One case with typical macrogranular morphologic features before therapy relapsed as the microgranular variant (M3v) ❚Image 1C❚ and ❚Image 1D❚. The blasts in this case did not exhibit changes in the immunophenotype, whereas an additional cytogenetic aberration, der(9) t(9;11)(q34;q13) was detected.
Discussion
With appropriate and timely therapy, remission can be achieved in patients with relapsed APL, rendering a prompt and accurate diagnosis essential. It has been presumed, quite reasonably, that APL at relapse is very similar to the disease before therapy. However, as far as we are aware, APL at relapse has not been the focus of systematic study. Therefore, we assessed the morphologic, immunophenotypic, cytogenetic, and molecular characteristics of relapsed APL and compared the findings with those at the time of original diagnosis to assess any differences with potential diagnostic or clinical significance.
Our results show that the morphologic type of the neoplastic promyelocytes in APL is usually stable over time. Only 1 of 38 cases in this study showed a change: from the typical macrogranular morphologic type at initial diagnosis to M3v at relapse. The reason for the observed change is unknown. Knowledge of this rare occurrence is important because morphologic changes could lead to misinterpretation, especially when evaluating BM aspirate specimens with minimal involvement at relapse. This potential pitfall can be avoided by performing a multifactorial evaluation, incorporating the results of molecular, cytogenetic, and immunophenotype studies in order that possible relapse not be missed.
Changes in the immunophenotype of the neoplastic promyelocytes at relapse were detected in almost all cases in which comparison with the initial diagnostic material was possible. These changes led to atypical immunophenotypes with positivity for CD34 or HLA-DR or decreased or absent expression of CD13 at relapse. These findings indicate that antibody panels that are not restricted to the initially detected markers should be used in the flow cytometric workup of APL at relapse. The reasons for the changes in immunophenotype are unknown but may reflect detection of the neoplastic populations at an earlier stage of maturation or acquisition of additional alterations of the blasts. In addition to the diagnostic implications, these immunophenotypic changes also may have therapeutic implications. In 2 of our cases, expression of CD33 was detected only at the time of recurrence, an interesting observation considering the fact that some new treatment regimens for APL incorporate agents targeting this surface marker. [6] [7] [8] The relative infrequency of MLL, FLT3, KIT, and RAS mutations in our APL cases suggests involvement of currently unknown pathways in the transformation and progression of APL. Identification of common chromosomal alterations may be helpful in this aspect. Chromosomal abnormalities in addition to t(15;17)(q22;q12) can occur in APL, with 1 study reporting a frequency of 26%, trisomy 8 being the most frequent. 17 In our study, 16 (55%) of 29 relapsed APL karyotypes included cytogenetically detectable chromosomal abnormalities in addition to t(15;17), most frequently affecting chromosomes 3, 8, 7, and 11. Both structural alterations and balanced translocations of chromosome 3, with breakpoints at 3q26 and 3q29, were identified. While chromosome 7 was involved in numerical and structural aberrancies occurring at first, second, and third relapse, aberrancies involving chromosome 8 were predominantly numeric-trisomy (2 cases) and monosomy (2 cases), 3 of which occurred at first relapse. Two abnormalities with the same breakpoint at chromosome 11q13 were detected at relapse: der(9)t(9;11)(q34;q13) and t(2;11) (q37;q13). In aggregate, these results point to the instability of the karyotype of APL over time and indicate probable ongoing clonal evolution.
In all cases in which a comparison between the initial diagnostic material and relapsed specimens was possible, the length of the fusion transcript detected by PCR remained unchanged. The consistency of the length of the PML-RARα fusion transcript can be helpful in excluding false-positive results as a result of cross-contamination in cases in which a transcript of a different size is detected in a follow-up sample from a particular patient. Of note, heterogeneity of the A B C D ❚Image 1❚ A, Bone marrow aspirate smear from a patient with acute promyelocytic leukemia at initial diagnosis. Several large promyelocytes with irregularly shaped to folded nuclei, dispersed chromatin, prominent nucleoli, and abundant cytoplasm with numerous fine granules are present (Wright-Giemsa, ×1,000). B, Cytochemical stain for myeloperoxidase. The neoplastic promyelocytes are positive, with diffuse and intense staining of the cytoplasmic granules partially covering the nuclear contours (×1,000). C, Bone marrow aspirate smear at relapse. The neoplastic promyelocytes are smaller, with markedly irregular nuclear contours, occasional visible nucleoli, and less abundant cytoplasm without granularity (Wright-Giemsa, ×1,000). D, Cytochemical stain for myeloperoxidase. The cytoplasm of the neoplastic promyelocytes demonstrates intensive staining (×1.000).
PML-RARα fusion transcript due to point mutations, resulting in variable patient response rates and differences in the propensity for acquiring additional aberrations with survival advantage, has been documented. 18, 19 However, these point mutations do not affect transcript size. In 28 cases, follow-up samples were assessed by RT-PCR before morphologic evidence of relapsed APL. In 10 cases (36%), results were positive for PML-RARα 1 to 7 months before morphologic relapse. Two cases never became negative for PML-RARα after induction therapy. This observation, together with the absence of influences from changes in the blast morphologic features or immunophenotype due to therapy, confirms the diagnostic usefulness of RT-PCR in the follow-up care of patients with APL. 20, 21 One previous study reported a median time to relapse in APL of 12.9 months. 10 We found a longer time to first relapse for APL, which was also significantly longer than that seen in patients with other types of acute myeloid leukemia (20.2 vs 9 months), probably reflecting the considerably higher efficacy of the new therapeutic approaches in APL. 22 We also noticed that the period of complete remission (time to subsequent relapse) decreased in patients in whom more than 1 relapse was documented (with a median of 15 months from first to second relapse and 9.5 months from second to third relapse). It seems reasonable to speculate that therapy-driven selection of more resistant clones over time occurred in these patients.
Recurrence of APL at extramedullary sites has been observed more frequently since the initiation of ATRA therapy and is detected in 3% to 12% of patients with APL. 6, 10, 23, 24 In our study, extramedullary relapse with or without concurrent BM disease was detected in 3.9% of all patients, representing 21% of patients with relapsed APL. In contrast, simultaneous extramedullary involvement was not present in any of 207 patients with APL at initial diagnosis. Extramedullary relapse was frequently isolated, without simultaneous BM disease. These findings may have some therapeutic implications, possibly suggesting that adding local radiotherapy to the treatment protocols could be a consideration in some cases. 8 In the literature, we identified a patient with 4 sequential isolated extramedullary relapses of APL at different sites of the body. 25 The 1 case in this study with extramedullary relapse involving bilateral external auditory canals is an oddity that has been reported previously. 10, 26, 27 In summary, despite the fact that APL is highly responsive to current therapy protocols, relapse is common, occurring in approximately 20% of patients in this study. Our results show that immunophenotypic and cytogenetic variations often occur over time. Knowledge of these changes may be helpful in avoiding misdiagnosis at the time of relapse. By contrast, the morphologic features and PCR transcript size are usually stable. These findings underline the importance of a multidisciplinary approach incorporating morphologic and ancillary studies in evaluating patients with APL at the time of relapse.
